BioLineRx Ltd (BLRX)

2.220
-0.100(-4.31%)
After Hours
2.200
-0.020(-0.901%)
- Real-time Data
  • Volume:
    703,023
  • Bid/Ask:
    2.200/2.300
  • Day's Range:
    2.150 - 2.376

BLRX Overview

Prev. Close
2.32
Day's Range
2.15-2.376
Revenue
-
Open
2.35
52 wk Range
2.15-6.34
EPS
-1.23
Volume
703,023
Market Cap
111.8M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
363,682
P/E Ratio
-
Beta
2.09
1-Year Change
-4.31%
Shares Outstanding
712,856,283
Next Earnings Date
Mar 09, 2022
What is your sentiment on BioLineRx Ltd?
or
Market is currently closed. Voting is open during market hours.

  • BioLineRx Earnings Miss, Revenue Inline In Q3
    • ByInvesting.com-

    Investing.com - BioLineRx reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. BioLineRx announced earnings...

  • biolinerx Q3 2021 Earnings Preview
    • BySeeking Alpha-

    biolinerx (NASDAQ:BLRX) is scheduled to announce Q3 earnings results on Wednesday, November 17th, after market close.The consensus EPS Estimate is -$0.13.Over the last 3 months,...

  • BioLineRx Earnings Beat, Revenue Inline In Q2
    • ByInvesting.com-

    Investing.com - BioLineRx reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations. BioLineRx announced earnings...

BioLineRx Ltd Company Profile

Employees
38

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellStrong Sell
Technical IndicatorsBuyNeutralStrong SellStrong SellStrong Sell
SummaryNeutralSellStrong SellStrong SellStrong Sell
  • They get fda fast track!!!
    0
    • Now it looks like my lucky ticket to the moon 🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝
      0
      • Get ready for the plane's take-off.
        0
        • I will not be a surprise, if this stock goes with 3 digit figures in the long run. lots of potential is hidden and should bustout anytime.
          0
          • journey begins...
            0
        • https://www.tipranks.com/stocks/blrx/forecast
          0
          • Do they really had good results ?The stock behavior say otherwise
            0
            • they will file for approval early next year, hopefully this will help it pick up again
              0
              • BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment
                0
                • Any chance that the result was overrated? How is us market reacting to the results?
                  0
                • Dong ThreeThousandNot overrated
                  0
                • If so this can hit $30 with ease
                  0
              • Only me?
                0
                • What r the reactions to the news? On US?
                  0
              • D*mn! Site frozen
                1
                • Any news??
                  0
                  • BLRX should be back in force from May 20th...keep holding, keep accommodating and keep patience. Price below 3 will be a dream later! Research and approvals is a long-term process...
                    0
                    • Samir you're breaking the car
                      0
                  • BIOLINERX LTD.   NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON APRIL 5, 2021  Whtat are you toughts?
                    1
                    • Going long, already up quite a bit and it is a lonely green island in a sea of red today.
                      0
                      • i was says the same before this big pull back, do you have any ideas news of the highest pt soon?
                        0
                    • Hello Neta, what do you think about BLRX? i am still holding long and strong
                      0
                      • Upcoming Significant Expected MilestonesTop-line results from the Phase 3 GENESIS trial in SCM in early Q2 2021.Initial results from Part 2 of the Phase 1/2a trial of AGI-134 in solid tumors in the second half of 2021.Pre-NDA meeting with the FDA for SCM in the second half of 2021NDA submission for SCM in the first half of 2022
                        0
                        • Announced positive results from an interim analysis of its GENESIS Phase 3 trial of motixafortide in stem-cell mobilization (SCM). The interim analysis found statistically significant evidence for the primary endpoint favoring treatment with motixafortide. Based on a recommendation from the independent Data Monitoring Committee (DMC), enrollment was ceased early at 122 patients (instead of 177 originally planned), and top-line data, including full primary and secondary efficacy endpoints, is anticipated in early second quarter of 2021. In parallel, the Company is proceeding with all activities in support of an NDA submission in this indication anticipated in the first half of 2022, including a pre-NDA meeting with the FDA planned for the second half of 2021.
                          0
                          • Any news on BLRX?
                            0
                            • No :( patience but slowly i lost the believe on this stock!
                              0
                            • Neta Goldberg thank you Neta, I think we have to keep the faith, I am holding long and strong BLRX or we made a mistake to not sell it at 4.25 weeks ago
                              0
                          • Green island in a sea of red today.
                            0
                            • Looks like an opportunity
                              0
                              • BLRX, EXPECT VERY GOOD NEWS TO ME FDA PHASE 3 OF MEDICATION, SO TIPRANKSThe analyst added, “We believe results from the Phase 3 GENESIS trial could spur the majority of transplant physicians to choose BL-8040 over Mozobil to combine with G-CSF if the drug is approved. Upside to our thesis includes BL-8040 for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company boasts a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck, and Genentech. ”
                                0
                                • Thank you to share Neta, I am holding BLRX long and strong
                                  0
                              • This will surely be up soon again. Small bumps are expected. Then it will ramp again, and if more positive news hits then it will sharply ascend.
                                0
                                • When is the fda approval?
                                  0
                                  • BLRX long term range intervals looks like: 5-12-22-50-70-100+
                                    0
                                    • BLRX should be back in force from May 20th...keep holding, keep accommodating and keep patience. Price below 3 will be a dream later! Research and approvals is a long-term process...
                                      0
                                  • Any comments?
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.